Progress towards the identification of new aggrecanase inhibitors

Current Medicinal Chemistry

Volumn 16, Issue 19, 2009, Pages 2395-2415

  De Rienzo, Francesca ^a,b   Saxena, Puneet ^a   Filomia, Federico ^a   Caselli, Gianfranco ^c   Colace, Fabrizio ^c   Stasi, Luigi ^c   Giordani, Antonio ^c   Menziani, Maria Cristina ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b INFM   (Italy)

^c Rotta Research Laboratorium   (Italy)

Author keywords

ADAMTS 4; ADAMTS 5; Aggrecanase; Inhibitors; Structure activity relationships

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 HYDROXY 4 ARYLSULFONYLTETRAHYDROPYRANYL 3 HYDROXAMATE; 3,3 DIMETHYL 5 HYDROXYPIPECOLIC HYDROXAMATE; A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN 4; A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN 5; ADAM PROTEIN; AGGRECANASE; AGGRECANASE INHIBITOR; BATIMASTAT; BIPHENYLSULFONAMIDE CARBOXYLATE INHIBITOR; CGS 27023A; CHELATING AGENT; ENZYME INHIBITOR; IMIDAZOLIDINENIONE; MARIMASTAT; METALLOPROTEINASE INHIBITOR; PRINOMASTAT; SUCCINYLHYDROXAMATE; SULFONAMIDE HYDROXAMATE; THIOXOTHIAZOLIDINONE; UNCLASSIFIED DRUG;

BINDING SITE; CALCIUM BINDING; CATALYSIS; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION;

AGGRECANS; AMINO ACID SEQUENCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; ENDOPEPTIDASES; HUMANS; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349378351     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788682092     Document Type: Review

References (67)

1. Martel-Pelletier, J. Pathophysiology of osteoarthritis. Osteoar. Cartil., 1999, 7, 371-73.
2. Glodring, M.B.; Glodring, S.R. Osteoarthritis. J. Cell. Physiol., 2007, 213, 3, 626-34.
3. Felson, D.T.; Neogi, T. Osteoarthritis: Is it a disease of cartilage or of bone? Arthritis Rheum., 2004, 50, 341-44.
4. Aigner, T.; Kurz, B.; Fukui, N.; Sandell, L. Roles of chondrocytes in the pathogenesis of osteoarthritis. Curr. Opin. Rheumatol., 2002, 14, 5, 578-84.
5. Daouti, S.; Latario, B.; Nagulapalli, S.; Buxton, F.; Uziel-Fusi, S.; Chirn, G.W.; Bodian, D.; Song, C.; Labow, M.; Lotz, M.; Quintavalla, J.; Kumar, C. Development of comprehensive functional genomic screens to identify novel mediators of osteoarthritis. Osteoar. Cartil., 2005, 13, 6, 508-18.
6. Fajardo, M.; Di Cesare, P.E. Disease-modifying therapies for osteoarthritis: Current status. Drugs Aging, 2005, 22, 141-61.
7. Singh, G. Treatment options for osteoarthritis. Surg. Technol. Int., 2003, 11, 287-92.
8. Sweet, B.V.; Townsend, K.A.; Tsai, C.Y. Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients. Am. J. Health Syst. Pharm., 2004, 61, 1917-21.
9. Mamdani, M.; Juurlink, D.N.; Lee, D.S.; Rochon, P.A.; Kopp, A.; Naglie, G.; Austin, P.C.; Laupacis, A.; Stukel, T.A. Cyclooxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet, 2004, 363, 1751-56.
10. Pelletier, M.J.; Boileau, C.; Pelletier, J.P.; Roughley, P.J. Cartilage in normal and osteoarthritis conditions. Best Pract. Res. Clin. Rheumatol., 2008, 22, 351-84.
11. Hardingham, T. Extracellular matrix and pathogenic mechanisms in osteoarthritis. Curr. Rheumatol. Rep., 2008, 10, 30-36.
12. Kiani, C.; Chen, L.; Wu, Y.J.; Yee, A.J.; Yang, B.B. Structure and function of aggrecan. Cell Res., 2002, 12, 19-32
13. Hardingham, T.E.; Fosang, A.J.; Dundhia, J. The structure, function and turnover of aggrecan, the large aggregating proteoglycan from cartilage. Eur. J. Clin Chem. Clin. Biochem., 1994, 32, 249- 7.
14. Brissett, N.C.; Perkins, S.J. The protein fold of the hyaluronate-binding proteoglycan tandem repeat domain of link protein, aggrecan and CD44 is similar to that of the C-type lectin superfamily. FEBS Lett., 1996, 388, 211-16.
15. Roughley, P.J. The structure and function of cartilage proteoglycans. Eur. Cell Mat., 2006, 12, 92-101.
16. Dundhia, J. Aggrecan, aging and assembly in articular cartilage. Cell. Mol. Life Sci., 2005, 62, 2241-56.
17. Watanabe, H.; Gao, L.; Sugiyama, S.; Doege, K.; Kimata, K.; Yamada, Y. Mouse aggrecan, a large cartilage proteoglycan: Protein sequence, gene structure and promoter sequence. Biochem. J., 1995, 308, 433-40.
18. Sandy, J.D.; Flannery, C.R.; Neame, P.J.; Lohmander, L.S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J. Clin. Invest., 1992, 89, 1512-16.
19. Lohmander, L.S.; Neame, P.J.; Sandy, J.D. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum., 1993, 36, 1214-22.
20. Sandy, J.D.; Verscharen, C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. J. Biochem., 2001, 358, 615-26.
21. Little, C.B.; Meeker1, C.T.; Golub, S.B.; Lawlor, K.E.; Farmer, P.J.; Smith, S.M.; Fosang, A.J. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J. Clin. Invest., 2007, 117, 1627-36.
22. Tortorella, M.D.; Burn, T.C.; Pratta, M.A.; Abbaszade, I.; Hollis, J. M.; Liu, R.; Rosenfeld, S.A.; Copeland, R.A.; Decicco, C.P.; Wynn, R.; Rockwell, A.; Yang, F.; Duke, J.L.; Solomon, K.; George, H.; Bruckner, R.; Nagase, H.; Itoh, Y.; Ellis, D.M.; Ross, H.; Wiswall, B.H.; Murphy, K.; Hillman, M.C., Jr.; Hollis, G.F.; Newton, R.C.; Magolda, R.L.; Trzaskos, J.M.; Arner, E.C. Purification and Cloning of Aggrecanase-1: A Member of the ADAMTS Family of Proteins. Science, 1999, 284, 1664-66.
23. Abbaszade, I.; Liu, R.Q.; Yang, F.; Rosenfeld, S.A.; Ross, O.H.; Link, J.R.; Ellis, D.M.; Tortorella, M.D.; Pratta, M.A.; Hollis, J.M.; Wynn, R.; Duke, J.L.; George, H.J.; Hillman, M.C.Jr.; Murphy, K.; Wiswall, B.H.; Copeland, R.A.; Decicco, C.P.; Bruckner, R.; Nagase, H.; Itoh, Y., Newton, R.C.; Magolda, R.L.; Trzaskos, J.M.; Burn, T.C. Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family. J. Biol. Chem., 1999, 274, 23443-50.
24. Porter, S.; Clark, I.M.; Kevorkian, L.; Edwards, D.R. The ADAMTS metalloproteinases. Biochem. J., 2005, 386, 15-27
25. Gerhardt, S.; Hassall, G.; Hawtin, P.; Mccall, E.; Flavell, L.; Minshull, C.; Hargreaves, D.; Ting, A.; Pauptit, R.A.; Parker, A.E.; Abbott, W.M. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J. Mol. Biol., 2007, 373, 891-902.
26. Mosyak, L.; Georgiadis, K.; Shane, T.; Svenson, K.; Hebert, T.; McDonagh, T.; Mackie, S.; Olland, S.; Lin, L.; Zhong, X.; Kriz, R.; Reifenberg, E.L.; Collins-Racie, L.A.; Corcoran, C.; Freeman, B.; Zollner, R.; Marvell, T.; Vera, M.; Sum, P.E.; Lavallie, E.R.; Stahl, M.; Somers, W. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci., 2008, 17, 16-21.
27. Shieh, H.-S.; Mathis, K.J.; Williams, J.M.; Hills, R.L.; Wiese, J.F.; Benson, T.E.; Kiefer, J.R.; Marino, M.H.; Carroll, J.N.; Leone, J.W.; Malfait, A.M.; Arner, E.C.; Tortorella, M.D.; Tomasselli, A. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J. Biol. Chem., 2008, 283, 1501-07.
28. Stocker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Rüth, F.X.; McKay, D.B.; Bode, W. The metzincins - topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci., 1995, 4, 823-40.
29. Seals, D. F.; Courtneidge, S. A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev., 2003, 17, 7-30.
30. Kuno, K.; Kanada, N.; Nakashima, E.; Fujiki, F.; Ichimura, F.; Matsushima, K. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J. Biol. Chem., 1997, 272, 556-62.
31. Hurskainen, T.L.; Hirohata, S.; Seldin, M.F.; Apte, S.S. ADAMTS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J. Biol. Chem., 1999, 274, 25555-63.
32. Andreini, C.; Banci, L.; Bertini, I.; Elmi, S.; Rosato, A. Comparative analysis of the ADAM and ADAMTS families. J. Proteome Res., 2005, 4, 881-88.
33. Nicholson, A.C.; Malik, S.-B.; Logdson, J.M.Jr.; Van Meir, E.G. Functional evolution of ADAMTS genes: Evidence from analyses of phylogeny and gene organization. BMC Evol. Biol., 2005, 5, 11-23.
34. Tortorella, M.D.; Malfait, A.M. Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. Curr. Pharm. Biotechnol., 2008, 9, 16-23.
35. Fosang, A.J.; Rogerson, F.M.; East, C.J.; Stanton, H. ADAMTS-5: The story so far. Eur. Cell Mat., 2008, 15, 11-26.
36. Rush III, T.S.; Powers, R. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors. Curr. Top. Med. Chem., 2004, 4, 1311-27.
37. Mosyak, L.; Rush III, T.S. Aggrecanase Structure. WO patent 025248, 2007.
38. Kumar, S.; Ma, B.; Tsai, C.J.; Sinha, N.; Nussinov, R. Folding and binding cascades: Dynamic landscapes and population shifts. Protein Sci., 2000, 9, 10-19.
39. Ma, B.; Shatsky, M.; Wolfson, H.J.; Nussinov, R. Multiple diverse ligands binding at a single protein site: A matter of pre-existing populations. Protein Sci., 2002, 11, 184-97.
40. Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, A.G.H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev., 1999, 99, 2735-76.
41. Renkiewicz, R.; Qiu, L.; Lesch, C.; Sun, X.; Devalaraja, R.; Cody, T.; Kaldjian, E.; Welgus, H.; Baragi, V. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum., 2003, 48, 1742-49.
42. Peterson, J.T., The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res., 2006, 69, 677-87.
43. Yao, W.; Wasserman, Z.R.; Chao, M.; Reddy, G.; Shi, E.; Liu, R.-Q.; Covington, M.B.; Arner, E.C.; Pratta, M.A.; Tortorella, M.; Magolda, R.L.; Newton, R.; Qian, M.; Riba-deneira, M.D.; Christ, D.; Wexler, R.R.; Decicco, C.P. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)-[(1S,2R)-2-hydroxy-2,3- dihydro-1H-inden-1-yl] butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. J. Med. Chem., 2001, 44, 3347-50.
44. Yao, W.; Chao, M.; Wasserman, Z.R.; Liu, R.Q; Covington, M.B.; Newton, R.; Christ, D.; Wexler R.R.; Decicco, C.P. Potent P1' biphenylmethyl substituted aggrecanase inhibitors. Bioorg. Med. Chem. Lett., 2002, 12, 101-04.
45. Cherney, R.J.; Mo, R.; Meyer, D.T.; Wang, L.; Yao, W., Wasserman, Z.R.; Liu, R.Q.; Covington, M.B.; Tortorella, M.D.; Arner, E.C.; Qian, M.; Christ, D.D.; Trzaskos, J.M.; Newton, R.C.; Magolda, R.L.; Decicco, C.P. Potent and selective aggrecanase inhibitors containing cyclic P1 substituents. Bioorg. Med. Chem. Lett., 2003, 13, 1297-300.
46. Dickens, J.P.; Donald, D.K.; Kneen, G.; Mckay, W.R. Hydroxamic acid based collagenase inhibitors. U.S. Patent 4599361, 1986.
47. Fosang, A.J.; Last, K.; Neame, P.J.; Murphy, G.; Knaeuper, V.; Tschesche, H.; Hughes, C.E.; Caterson, B.; Hardingham, T.E. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. Biochem. J., 1994, 304, 347-51.
48. Nagase, H.; Fields, G.B. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers, 1996, 40, 399-416.
49. Tortorella, M.; Pratta, M.; Liu, R-Q.; Abbaszade I.; Ross H.; Burn T.; Arner E. The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J. Biol. Chem., 2000, 275, 25791-97.
50. Miller, J.A.; Arner, E.C.; Copeland, R.A.; Davis, G.L.; Pratta, M.; Tortorella, M.D. Assays and peptide substrate for determining aggrecan degrading metallo protease activity. WO patent 005256, 2000.
51. Xue, C.-B.; Voss, M.E.; Nelson, D.J.; Duan, J.J.W.; Cherney, R.J.; Jacobson, I.C.; He, X.; Roderick, J.; Chen, L.; Corbett, R.L.; Wang, L.; Meyer, D.T.; Kennedy, K.; DeGrado, W.F.; Hardman, K.D.; Teleha, C.A.; Jaffee, B.D.; Liu, R.-Q.; Copeland, R.A.; Covington, M.B.; Christ, D.D.; Trzaskos, J.M.; Newton, R.C.; Magolda, R.L.; Wexler, R.R.; Decicco, C.P. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J. Med. Chem., 2001, 44, 2636-60.
52. Njoroge, F.G.; Fox, J.W.; Bode, W.; Meyer, E.F. Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d). Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 8447-51.
53. Gomis-Ruth, F.X.; Kress, L.F.; Kellermann, J.; Mayr, I.; Huber, R.; Bode, W. Refined 2.0 A X-ray crystal structure of the snake venom zinc-endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin. J. Mol. Biol., 1994, 239, 513-44.
54. Hirayama, R.; Yamamoto, M.; Tsukida, T.; Matsuo, K.; Obata, Y.; Sakamoto, F.; Ikeda, S. Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors. Bioorg. Med. Chem., 1997, 5, 765-78.
55. MacPherson, L.J.; Bayburt, E.K.; Capparelli, M.P.; Carroll, B.J.; Goldstein, R.; Justice, M.R.; Zhu, L.; Hu, S-I; Melton, R.A.; Fryer, L.; Goldberg, R.L.; Doughty, J.R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E.M.; Ganu, V.; Parker, D.T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem., 1997, 40, 2525-32.
56. Noe, M.C.; Snow, S.L.; Wolf-Gouveia, L.A.; Mitchell, P.G.; Lopresti-Morrow, L.; Reeves, L.M.; Yocum, S.A.; Liras, J.L.; Vaughn, M. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase. Bioorg. Med. Chem. Lett., 2004, 14, 4727-30.
57. Letavic, M.A.; Axt, M.Z.; Barberia, J.T.; Carty, T.J.; Danley, D.E.; Geoghegan, K.F.; Halim, N.S.; Hoth, L.R.; Kamath, A.V.; Laird, E.R.; Lopresti-Morrow, L.L.; McClure, K.F.; Mitchell, P.G.; Natarajan, V.; Noe, M.C.; Pandit, J.; Reeves, L.M.; Schulte, G.K.; Snow, S.L.; Sweeney, F.J.; Tan, D.H.; Yu, C.H. Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors. Bioorg. Med. Chem. Lett., 2002, 12, 1387-90.
58. Venkatesan, A.; Davis, J.M.; Grosu, G.T.; Baker, J.; Ellingboe, J.; Zask, A.; Levin, J.I.; Sandanayaka, V.P.; Du, M.; Skotnicki, J.S.; DiJoseph, J.F.; Sung, A.; Sharr, M.A.; Killar, L.M.; Walter, T.; Jin, G.; Cowling, R.; Tillett, J.; Zhao, W.; McDevitt, J.; Xu, Z.B. Synthesis and Structure - Activity Relationship of N-Substituted 4-Arylsulfonylpiperidine-4-hydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis. J. Med. Chem., 2003, 46, 2376-96.
59. Noe, M.C.; Natarajan, V.; Snow, S.L.; Mitchell, P.G.; Lopresti-Morrow, L.L.; Reeves, L.M.; Yocum, S.A.; Carty, T.J.; Barberia, J.T.; Sweeney, F.J.; Liras, J.L.; Vaughn, M.; Hardink, J.; Hawkins, J.M.; Tokar, C. Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13. Bioorg. Med. Chem. Lett., 2005, 15, 2808-11.
60. Noe, M.C.; Natarajan, V.; Snow, S.L.; Wolf-Gouveia, L.A.; Mitchell, P.G.; Lopresti-Morrow, L.; Reeves, L.M.; Yocum, S.A.; Otterness, I.; Bliven, M.A.; Carty, T.J.; Barberia, J.T.; Sweeney, F.J.; Liras, J.L.; Vaughn, M. Discovery of 3-OH-3-methylpipecolic hydroxamates: Potent orally active inhibitors of aggrecanase and MMP-13. Bioorg. Med. Chem. Lett., 2005, 15, 3385-88.
61. Xiang, J.S.; Hu, Y.; Rush, T.S.; Thomason, J.R.; Ipek, M.; Sum, P.-E.; Abrous, L.; Sabatini, J.J.; Georgiadis, K.; Reifenberg, E.; Majumdar, M.; Morris, E.A.; Tam, S. Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 311-16.
62. MacPherson, L.J.; Bayburt, E.K.; Capparelli, M.P.; Carroll, B.J.; Goldstein, R.; Justice, M.R.; Zhu, L.; Hu, S.-I.; Melton, R.A.; Fryer, L.; Goldberg, R.L.; Doughty, J.R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E.M.; Ganu, V.; Parker, D.T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem., 1997, 40, 2525-32.
63. Pratta, M. A.; Yao, W.; Decicco, C.; Tortorella, M. D.; Liu, R.-Q.; Copeland, R. A.; Magolda, R.; Newton, R. C.; Trzaskos, J. M.; Arner, E. C. Aggrecan protects cartilage collagen from proteolytic cleavage. J. Biol. Chem., 2003, 278, 45539-45.
64. Little, C.; Hughes, C.; Curtis, C.; Janusz, M.; Bohme, R.; Wang-Weigand, S.; Taiwo, Y.; Mitchell, P.; Otterness, I.; Flannery, C.; Caterson, B. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol., 2002, 21, 271-88.
65. Bursavich, M.G.; Gilbert, A.M.; Lombardi, S.; Georgiadis, K.E.; Reifenberg, E.; Flannery, C.R.; Morris, E.A. Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorg. Med. Chem. Lett., 2007, 17, 1185-88.
66. Gilbert, A.M.; Bursavich, M.G.; Lombardi, S.; Georgiadis, K.E.; Reifenberg, E.; Flannery, C.R.; Morris, E.A. 5-((1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5. Bioorg. Med. Chem. Lett., 2007, 17, 1189-92.
67. Bursavich, M.G.; Gilbert, A.M.; Lombardi, S.; Georgiadis, K.E.; Reifenberg, E.; Flannery, C.R.; Morris, E.A.